You are here: Industry Insights > Novavax

News List

Novavax Seeks Approval for Vaccine in Needy Countries First drugs
August 09, 2021
Novavax said Thursday that it has applied for emergency use approval of its COVID-19 vaccine in India, Indonesia, and the Philippines.
Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine prnasia
August 06, 2021
Novavax, Inc. today announced that the companies have filed regulatory submissions for emergency use authorization of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant.
Novavax and European Commission finalise advance purchase agreement for up to 200 million doses of COVID-19 vaccine expresspharma
August 06, 2021
Novavax has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine prnasia
August 05, 2021
Novavax announced that it has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant.
Novavax’ COVID-19 vaccine almost 90 percent effective in Phase III trials europeanpharmaceuticalreview
July 02, 2021
In UK trials where 60 percent of COVID-19 cases were caused by the Alpha SARS-CoV-2 variant, the NVX-CoV2373 COVID-19 vaccine was 89.7 percent effective.
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine firstwordpharma
July 01, 2021
Novavax today announced the publication of results from the final analysis of a pivotal Phase 3 clinical trial of its COVID-19 vaccine candidate conducted in the United Kingdom in the New England Journal of Medicine (NEJM).
Novavax Statement on Completion of the National Research Council of Canada Biologics Manufacturing Centre firstwordpharma
June 23, 2021
The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry announced today that construction of the new Biologics Manufacturing Centre (BMC) at the National Research Council of Canada's (NRC)’s Royalmount location.
Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine drugs
June 21, 2021
Novavax, Inc. today announced preclinical and clinical data on the company's original recombinant protein COVID-19 vaccine candidate, NVX-CoV2373, and for a new vaccine directed against the SARS-CoV-2 Beta (B.1.351) variant.
Study demonstrates safety and efficacy of co-administering COVID-19 and flu vaccines pharmatimes
June 18, 2021
A study conducted by Novavax has found that co-administering a COVID-19 vaccine with a flu vaccine is safe and effective, with the efficacy of both jabs appearing to be preserved.
Influenza Vaccine and Novavax COVID-19 Vaccine Simultaneous Administration Yields Positive Results americanpharmaceuticalreview
June 17, 2021
Novavax Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax, NVX-CoV2373] and an approved influenza vaccine ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page